PTGX - Protagonist Therapeutics, Inc

QQQ $ 452.41 $ 0.71 (0.16 %)

DIA $ 394.39 $ -1.21 (-0.31 %)

SPY $ 534.14 $ -0.48 (-0.09 %)

TLT $ 96.56 $ 0.56 (0.58 %)

GLD $ 227.77 $ 1.65 (0.73 %)

Previous Close

$ 38.72

Open

$ 39.11

Bid

$ 40.41 x 100

Ask

-- x --

Day's Range

$ 38.42 - $ 40.78

52 Week Range

$ 13.72 - $ 42.67

Volume

1,063,510

Average Volume

Market Cap

2.37B

Beta (5Y Monthly)

$ 1.36

PE Ratio (TTM)

$ 13.97

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-06-2024	06-30-2024	10-Q
2	05-07-2024	03-31-2024	10-Q
3	02-27-2024	12-31-2023	10-K
4	11-02-2023	09-30-2023	10-Q
5	08-03-2023	06-30-2023	10-Q
6	05-04-2023	03-31-2023	10-Q
7	03-15-2023	12-31-2022	10-K
8	11-08-2022	09-30-2022	10-Q
9	08-04-2022	06-30-2022	10-Q
10	05-05-2022	03-31-2022	10-Q
11	02-28-2022	12-31-2021	10-K
12	11-03-2021	09-30-2021	10-Q
13	08-04-2021	06-30-2021	10-Q
14	05-04-2021	03-31-2021	10-Q
15	03-10-2021	12-31-2020	10-K
16	11-04-2020	09-30-2020	10-Q
17	08-06-2020	06-30-2020	10-Q
18	05-07-2020	03-31-2020	10-Q
19	03-10-2020	12-31-2019	10-K
20	11-06-2019	09-30-2019	10-Q
21	08-07-2019	06-30-2019	10-Q
22	05-08-2019	03-31-2019	10-Q
23	03-12-2019	12-31-2018	10-K
24	11-06-2018	09-30-2018	10-Q
25	08-07-2018	06-30-2018	10-Q
26	05-09-2018	03-31-2018	10-Q
27	03-07-2018	12-31-2017	10-K
28	11-07-2017	09-30-2017	10-Q
29	08-08-2017	06-30-2017	10-Q
30	05-10-2017	03-31-2017	10-Q
31	03-07-2017	12-31-2016	10-K
32	11-14-2016	09-30-2016	10-Q
33	09-15-2016	06-30-2016	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

JMP Securities Maintains Market Outperform...
08/07/2024 20:37:35

JMP Securities analyst Jonathan Wolleben maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Market Outperform and lower...

HC Wainwright & Co. Maintains Buy on Prota...
08/07/2024 20:26:35

HC Wainwright & Co. analyst Douglas Tsao maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and raises the pric...

Protagonist Says Cash And Equivalents Of $...
08/06/2024 11:53:20

Protagonist Therapeutics Q2 2024 GAAP EPS ...
08/06/2024 11:52:31

Protagonist Therapeutics (NASDAQ:PTGX) reported quarterly losses of $(0.50) per share which beat the analyst consensus estimate...

viasat--ast-spacemobile-are-among-top-6-mid-cap-stocks-that-shined-the-brightest-last-week-july-21-july-27-are-the-others-in-your-portfolio

ViaSat & AST SpaceMobile Are Among Top 6 M...
07/28/2024 18:17:42

Top mid-cap stocks of the week: ASTS up 47.88%, GSHD up 39.86%, VSAT up 30.78%, VKTX up 29.86%, BEAM up 23.93%, CLDX up 19.72%

JP Morgan Maintains Overweight on Protagon...
07/25/2024 14:08:21

JP Morgan analyst Brian Cheng maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Overweight and raises the price target...

att-group-1-automotive-mattel-seagate-and-other-big-stocks-moving-higher-on-wednesday

AT&T, Group 1 Automotive, Mattel, Seagate ...
07/24/2024 14:46:56

BTIG Maintains Buy on Protagonist Therapeu...
07/24/2024 13:33:32

BTIG analyst Julian Harrison maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and raises the price target from $4...

Market-Moving News for June 28th
06/28/2024 12:37:11

PTGX: 11% | Protagonist Therapeutics To Join S&P SmallCap 600, Effective Prior To Opening Of Trading On July 3 DJT: 16% | ...

Protagonist Therapeutics To Join S&P Small...
06/27/2024 21:21:08

Protagonist Therapeutics to replace Encore Wire in the S&P SmallCap 600 effective prior to the opening of trading on Wedne...

JMP Securities Reiterates Market Outperfor...
06/17/2024 12:21:06

JMP Securities analyst Jonathan Wolleben reiterates Protagonist Therapeutics (NASDAQ:PTGX) with a Market Outperform and main...

HC Wainwright & Co. Reiterates Buy on Prot...
06/14/2024 17:11:19

HC Wainwright & Co. analyst Douglas Tsao reiterates Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and maintains $38 ...

Protagonist Presents Updated Long-Term Fin...
06/14/2024 08:04:37

Protagonist Therapeutics Presents Long-Ter...
05/14/2024 20:28:33

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or the "Company") today announced that additional d...

HC Wainwright & Co. Reiterates Buy on Prot...
05/09/2024 19:00:45

HC Wainwright & Co. analyst Douglas Tsao reiterates Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and maintains $38 ...

JMP Securities Maintains Market Outperform...
05/08/2024 18:09:56

JMP Securities analyst Jonathan Wolleben maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Market Outperform and raise...

Protagonist Therapeutics Q1 EPS $3.26, Sal...
05/07/2024 20:58:54

Protagonist Therapeutics Has Randomized 24...
03/26/2024 11:17:51

Protagonist Therapeutics Closes Worldwide ...
03/18/2024 11:12:53

HC Wainwright & Co. Maintains Buy on Prota...
03/11/2024 16:15:26

HC Wainwright & Co. analyst Douglas Tsao maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and maintains $38 p...